[1] Hu F, Chen X, Liu X, et al. Clinicopathological features and prognostic implications of Raf kinase inhibitor protein downregulation in tongue squamous cell carcinoma[J]. Oncol Lett, 2015, 10(3):1303-1308.
[2] 黄江峰, 何保昌, 陈法, 等. 口腔卫生状况及慢性病与口腔鳞状细胞癌的关系研究[J]. 中华预防医学杂志, 2015, 49(8):688-692.
[3] Zhang C, Shu L, Kong AT. MicroRNAs: new players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways[J]. Curr Pharmacol Rep, 2015, 1(1):21-30.
[4] Xu F, Xu L, Wang M, et al. The accuracy of circulating microRNA-21 in the diagnosis of colorectal cancer: a systematic review and meta-analysis[J]. Colorectal Dis, 2015, 17(5):100-107.
[5] Manikandan M, Deva Magendhra Rao AK, Rajkumar KS, et al. Altered levels of miR-21, miR-125b-2*, miR-138, miR-155, miR-184, and miR-205 in oral squamous cell carcinoma and association with clinicopathological characteristics[J]. J Oral Pathol Med, 2015, 44(10):792-800.
[6] Jamali Z, Asl Aminabadi N, Attaran R, et al. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis[J]. Oral Oncol, 2015, 51(4):321-331.
[7] Lodewijk L, Prins AM, Kist JW, et al. The value of miRNA in diagnosing thyroid cancer: a systematic review[J]. Cancer Biomark, 2012, 11(6):229-238.
[8] 郭柏华, 唐云, 陈力, 等. 甲状腺乳头状癌组织中 miR-21的表达与临床预后的关系[J]. 中国急救复苏与灾害医学杂志, 2015, 10(3):247-249.
[9] Li Y, Yan L, Zhang W, et al. miR-21 inhibitor suppresses proliferation and migration of nasopharyngeal carcinoma cells through down-regulation of BCL2 expression[J]. Int J Clin Exp Pathol, 2014, 7(6):3478-3487.
[10] Hu A, Huang JJ, Xu WH, et al. MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma[J]. Am J Cancer Res, 2015, 5(5):1775-1785.
[11] 李莎莎, 周旋, 张强, 等. STAT3与miRNA-21在舌鳞状细胞癌中异常表达的相关性研究[J]. 中国肿瘤临床, 2013, 40(6):323-327.
[12] Wang Y, Zhu Y, Lv P, et al. Targeting miR-21 with AS-miR-21 suppresses aggressive growth of human tongue squamous cell carcinoma in vivo[J]. Int J Clin Exp Pathol, 2015, 8(5):4773-4781.
[13] Zhang X, Hao J. Development of anticancer agents targeting the Wnt/β-catenin signaling[J]. Am J Cancer Res, 2015, 5(8):2344-2360.
[14] Prakash S, Swaminathan U. β catenin in health: a review[J]. J Oral Maxillofac Pathol, 2015, 19(2):230-238.
[15] Wolf E, Lin CY, Eilers M, et al. Taming of the beast: shaping Myc-dependent amplification[J]. Trends Cell Biol, 2015, 25(4):241-248.
[16] Rachner TD, G?bel A, Benad-Mehner P, et al. Dickkopf-1 as a mediator and novel target in malignant bone disease[J]. Cancer Lett, 2014, 346(2):172-177. |